Ee. Soltis, ALTERATIONS IN VASCULAR STRUCTURE AND FUNCTION AFTER SHORT-TERM LOSARTAN TREATMENT IN SPONTANEOUSLY HYPERTENSIVE RATS, The Journal of pharmacology and experimental therapeutics, 266(2), 1993, pp. 642-646
The current study was performed to investigate the effects of a 2-week
treatment regimen with either hydralazine or the nonpeptide angiotens
in II subtype 1 receptor antagonist losartan (both at 1 0 mg/kg daily
s.c. injection) on blood pressure and vascular smooth muscle function
and structure in male spontaneously hypertensive rats with established
hypertension (24 weeks of age; systolic blood pressure = 174 +/- 7 mm
Hg). Systolic blood pressure and body weight were recorded before and
once weekly after initiation of treatment. Mean arterial pressure, he
art rate and heart weight were determined and experiments were conduct
ed to assess changes in vascular reactivity and arterial medial thickn
ess in ring segments of aorta and tail artery at the end of the treatm
ent period. Systolic blood pressure, as well as mean arterial pressure
, were significantly decreased to normotensive levels in hypertensive
rats after 2 weeks of either hydralazine or losartan treatment. No eff
ect on heart rate was observed in response to either antihypertensive
agent. Body weight was not affected in either of the treatment groups,
but a significant decrease in artery ring weight, arterial medial thi
ckness and heart weight was seen only in losartan-treated rats. Wherea
s no changes in vascular reactivity were seen in hypertensive rats rec
eiving hydralazine, norepinephrine- and serotonin-induced contractions
were attenuated and acetylcholine-induced relaxations were enhanced i
n the losartan-treated rats. These data demonstrate that, although sho
rt-term 2-week treatment with either hydralazine or losartan results i
n normalization of blood pressure, only losartan resulted in significa
nt alterations in vascular function and structure in spontaneously hyp
ertensive rats. The observations support the hypothesis that angiotens
in 11 plays a significant role in the maintenance of hypertension and
cardiovascular hypertrophy in this model.